首页 | 本学科首页   官方微博 | 高级检索  
检索        

重组红细胞生成素治疗早产儿贫血36例的临床分析
引用本文:杨敏.重组红细胞生成素治疗早产儿贫血36例的临床分析[J].中国药业,2013(6):35-36.
作者姓名:杨敏
作者单位:浙江省台州市立医院新生儿科,浙江台州318000
摘    要:目的探讨重组红细胞生成素治疗早产儿贫血的临床疗效。方法选择2010年1月至2011年12月收治的胎龄不小于36周的早产儿72例,随机分成两组,各36例。对照组给予每日口服维生素C和E各25 mg、铁剂5 mg/kg等常规治疗,治疗组在此基础上于出生后的第1周给予重组红细胞生成素600 IU/kg皮下注射,每周3次,隔日1次,共6周。比较两组早产儿的输血率、体重增长情况及血常规变化。结果治疗组输血率(16.67%)低于对照组(47.22%,P<0.05);体重增长速率显著高于对照组(P<0.05);用药后血红蛋白、红细胞压积、网织红细胞显著高于对照组(P<0.05);血清铁蛋白水平显著低于对照组(P<0.05)。结论重组红细胞生成素可有效防治早产儿贫血,减少输血次数,快速增长早产儿体重,安全性高,值得临床推广。

关 键 词:重组红细胞生成素  早产儿  贫血

Application Analysis on Recombinant Erythropoietin in Treatment of Prematurity Anemia
Yang Min.Application Analysis on Recombinant Erythropoietin in Treatment of Prematurity Anemia[J].China Pharmaceuticals,2013(6):35-36.
Authors:Yang Min
Institution:Yang Min ( Department of Neonatology, Taizhou Municipal Hospital, Taizhou, Zhejiang, China 318000)
Abstract:Objective To study the clinical efficacy of recombinant erythropoietin for the treatment of anemia in premature in- fants. Methods 72 premature infants with the gestational age not less than 36 weeks treated in our hospital from January 2010 to De- cember 2011 were randomly divided into two groups,36 cases in each group. The control group was given the routine therapy of oral vitamin C and vitamin E, each 25 mg daily, and ferralia 5mg/kg, while on this basis, the treatment group was given recombinant ery- thropoietin 600 IU/kg by subcutaneous injection,once every other day,3 times per week for 6 weeks. The blood transfusion rate,weight gain and the change of blood routine were compared between the two groups of preterm infants. Results The blood transfusion rate was 16.67% in the treatment group,which was lower than 47.22% in the control group,the difference was statistically significant (P 〈 0. 05);the weight growth rate of the treatment group was significantly higher than that of the control group (P 〈 0. 05);hemoglobin (Hb),hematocrit (Hct) and reticuloeytes (Ret) after medication in the treatment group were significantly higher than those in the con- trol group,the difference showing statistical significance (P 〈 0.05);the serum ferritin (SF) level in the treatment group was signifi- cantly lower than that in the control group with statistical difference between the two groups (P 〈 0. 05). Conclusion Recombinant erythropoietin can effectively prevent and treat anemia in premature infants, reduce the frequency of blood transfusion and rapidly in- crease the body weight of premature infants with high safety,which is worthy of being popularized in clinical practice.
Keywords:recombinant erythropoietin  premature infants  anemia
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号